Alpha Tau CFO sells 20,000 shares

Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi sold 20,000 Ordinary Shares in an open-market transaction.

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi sold 20,000 Ordinary Shares in an open-market transaction. The shares were sold at an average price of $12.0022 per share. After this sale, Raphi directly holds 90,180 Ordinary Shares of Alpha Tau Medical.

Insights

Equity compensation and insider-trading analyst

CFO executes a single open-market share sale while retaining a sizeable position.

The filing shows Alpha Tau Medical CFO Levy Raphi completed an open-market sale of 20,000 Ordinary Shares at $12.0022 per share. This is a straightforward non-derivative transaction with no associated option exercises or derivative activity disclosed.

Following the sale, Raphi continues to hold 90,180 Ordinary Shares directly, indicating he retains meaningful equity exposure. With only one net-sale transaction and no derivative positions reported, this appears as a routine liquidity event rather than a structural change in insider ownership based on the available data.

Insider Trade Summary 10b5-1

Net Seller: 20,000 shares

Net Sell 1 txn

Insider Levy Raphi

Role Chief Financial Officer

Sold 20,000 shs ($240K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	20,000	$12.0022	$240K

Holdings After Transaction: Ordinary Shares — 90,180 shares (Direct)

Key Figures

Shares sold: 20,000 shares Sale price: $12.0022 per share Shares held after sale: 90,180 shares +1 more

4 metrics

Shares sold 20,000 shares Open-market sale of Ordinary Shares

Sale price $12.0022 per share Average sale price for 20,000 shares

Shares held after sale 90,180 shares Direct ownership following transaction

Net shares sold 20,000 shares Net-sell direction in transaction summary

Key Terms

Ordinary Shares, open-market sale, Form 4, non-derivative, +1 more

5 terms

Ordinary Shares financial

"The transaction involved 20,000 Ordinary Shares in a non-derivative sale."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market sale financial

"The filing characterizes the transaction as an open-market sale."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sale was reported on a Form 4 insider trading report."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"The transaction is classified as non-derivative with Ordinary Shares as the security."

direct ownership financial

"After the sale, the CFO holds 90,180 shares as direct ownership."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alpha Tau Medical (DRTS) disclose for Levy Raphi?

Alpha Tau Medical disclosed that CFO Levy Raphi sold 20,000 Ordinary Shares in an open-market transaction. The sale was reported on a Form 4 insider filing and reflects a direct, non-derivative disposition of the company’s Ordinary Shares by a senior executive.

At what price did the Alpha Tau Medical CFO sell DRTS shares?

The CFO sold 20,000 Alpha Tau Medical Ordinary Shares at an average price of $12.0022 per share. This price applies to the reported open-market sale and is the only transaction price disclosed in the Form 4 insider trading report for this event.

How many Alpha Tau Medical shares does the CFO hold after this sale?

After selling 20,000 Ordinary Shares, Alpha Tau Medical CFO Levy Raphi directly holds 90,180 Ordinary Shares. This post-transaction holding amount is disclosed in the Form 4 and represents his remaining direct ownership in the company’s equity following the reported sale.

Was the Alpha Tau Medical CFO transaction in derivatives or common equity?

The transaction involved non-derivative equity, specifically Ordinary Shares of Alpha Tau Medical. The Form 4 classifies it as a sale of non-derivative securities, with no accompanying option exercises, conversions, or other derivative security activity reported in the derivative section of the filing.

Does the Alpha Tau Medical Form 4 show multiple trades or a single transaction?

The Form 4 shows a single reported transaction: an open-market sale of 20,000 Ordinary Shares by the CFO. The transaction summary lists one sell transaction, with no recorded buys, gifts, tax withholdings, or restructuring events in this particular insider filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 08:21 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Raphi

(Last) (First) (Middle)

C/O ALPHA TAU MEDICAL

PO BOX 45044

(Street)

JERUSALEM 9777605

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alpha Tau Medical Ltd. [ DRTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/30/2026	06/30/2026	S		20,000	D	$12.0022	90,180	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Raphi Levy	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)